**Supplementary File**

**Supplementary Table 1.:** Countries GDP

|  |  |  |
| --- | --- | --- |
| **Country (blue - L-GDP, green – H-GDP)** | **GDP (GDP per capita $)** | **number of participants (%)** |
| Ukraine | 3659,03 | 40 |
| Albania | 5353,24 | 4 |
| Republic of North Macedonia | 6022,22 | 16 |
| Bosnia and Herzegovina | 6108,51 | 1 |
| Belarus | 6663,3 | 2 |
| Serbia | 7411,84 | 18 |
| Montenegro | 8908,93 | 1 |
| Turkey | 9126,56 | 49 |
| Bulgaria | 9828,15 | 21 |
| Russian Federation | 11585,00 | 41 |
| Romania | 12919,53 | 46 |
| Croatia | 14936,10 | 17 |
| Poland | 15692,51 | 48 |
| Hungary | 16731,82 | 18 |
| Latvia | 17828,89 | 35 |
| Slovakia | 19266,3 | 3 |
| Greece | 19582,54 | 144 |
| Lithuania | 19601,89 | 25 |
| Portugal | 23252,06 | 83 |
| Czech Republic | 23494,60 | 70 |
| Estonia | 23723,31 | 9 |
| Slovenia | 25946,18 | 27 |
| Cyprus | 27858,37 | 3 |
| Spain | 29600,38 | 30 |
| Malta | 29820,60 | 16 |
| Italy | 33228,24 | 82 |
| France | 40493,93 | 119 |
| Israel | 41715,03 | 17 |
| United Kingdom of Great Britain and Northern Ireland | 42330,12 | 72 |
| Belgium | 46420,66 | 45 |
| Germany | 46445,25 | 43 |
| Finland | 48782,79 | 2 |
| Austria | 50137,66 | 22 |
| Sweden | 51615,02 | 7 |
| Netherlands | 52331,32 | 43 |
| Denmark | 60170,34 | 32 |
| Norway | 75419,63 | 1 |
| Ireland | 78660,96 | 15 |
| Switzerland | 81993,73 | 13 |
| Luxembourg | 114704,59 | 5 |

**Supplementary Table 2.:** Drug monitoring

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Type of therapy** | **Proactive monitoring in H-GDP (%)** | **Proactive monitoring in L-GDP (%)** | **P value** | **Reactive monitoring in H-GDP (%)** | **Reactive monitoring in L-GDP (%)** | **P value** |
| **Infliximab** | 45.3 | 18.1 | **0.0001** | 87.4 | 46.0 | 0.0001 |
| **Adalimumab** | 36.9 | 12.4 | **0.0001** | 78.0 | 29.6 | **0.0001** |
| **Vedolizumab** | 9.5 | 1.9 | **0.0001** | 24.0 | 3.3 | **0.0001** |
| **Ustekinumab** | 5.5 | 2.1 | **0.002** | 15.7 | 1.6 | **0.0001** |
| **Thiopurines** | 21.3 | 4.2 | **0.0001** | 42.6 | 8.8 | **0.0001** |

**Supplementary Table 2b.:** Sensitivity analysis removing countries with <10 responders Drug monitoring

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Type of therapy** | **Proactive monitoring H-GDP (%)** | **Proactive monitoring in L-GDP (%)** | **P value** | **Reactive monitoring in H-GDP (%)** | **Reactive monotoring in L-GDP (%)** | **P value** |
| **Infliximab** | **72.4** | **40.9** | **0.0001** | **64.6** | **41.9** | **0.0001** |
| **Adalimumab** | **63.9** | **27.2** | **0.0001** | **63.9** | **27.2** | **0.0001** |
| **Vedolizumab** | **7.4** | **0.02** | **0.0001** | **35.7** | **7.5** | **0.0001** |
| **Ustekinumab** | **4.3** | **2.1** | **0.05** | **19.2** | **2.7** | **0.0001** |
| **Thiopurines** | **35.4** | **7.9** | **0.001** | **54.7** | **8.6** | **0.0001** |

**Supplementary Table 3.:** pre-biologic Monitoring

|  |  |  |  |
| --- | --- | --- | --- |
| **Tested diseases** | **High-GDP (%)** | **Low-GDP (%)** | **P value** |
| **Hepatitis A** | **39.9** | **43.1** | **0.29** |
| **Hepatitis B** | **98** | **96.4** | **0.09** |
| **Hepatitis C** | **93.3** | **92.3** | **0.55** |
| **Tuberculosis** | **97.8** | **93.8** | **0.0007** |
| **HIV** | **82.5** | **87.3** | **0.02** |
| **EBV** | **75.2** | **56.2** | **0.0001** |
| **VZV** | **63.4** | **37.6** | **0.0001** |
| **CMV** | **65.4** | **56.4** | **0.002** |

**Supplementary Table 3b.:** Sensitivity analysis removing countries <10

|  |  |  |  |
| --- | --- | --- | --- |
| **Tested diseases** | **High-GDP (%)** | **Low-GDP (%)** | **P Value** |
| **Hepatitis A** | **33.3** | **38.4** | **0.07** |
| **Hepatitis B** | **81.4** | **86.5** | **0.02** |
| **Hepatitis C** | **77.4** | **82.8** | **0.02** |
| **Tuberculosis** | **81.5** | **84.4** | **0.2** |
| **HIV** | **68.7** | **78.3** | **0.0002** |
| **EBV** | **60.6** | **49.8** | **0.0001** |
| **VZV** | **52.8** | **33.3** | **0.0001** |
| **CMV** | **54.4** | **50%** | **0.153** |

**Supplementary Table 4.:** Multidisciplinary board members

|  |  |  |  |
| --- | --- | --- | --- |
|  **Multidisciplinary board** | **High-GDP (%)** | **Low-GDP (%)** | **P value** |
| **Gastroenterologists** | **98.1** | **97.8** | **0.7** |
| **Colorectal surgeons** | **83.9** | **71.8** | **0.0006** |
| **IBD nurses** | **58.4** | **19.6** | **0.0001** |
| **Radiologists** | **69.5** | **67.5** | **0.6** |
| **Histopathologists** | **28.4** | **51** | **0.0001** |
| **Nutritional specialist** | **20.7** | **23.9** | **0.3** |
| **Psychologists** | **6.7** | **10.1** | **0.16** |
| **Pharmacist** | **10.3** | **7.4** | **0.24** |

**Supplementary Table 4b.:** Sensitivity analysis removing countries <10 responders GDP countries Multidisciplinary board members

|  |  |  |  |
| --- | --- | --- | --- |
| **Multidisciplinary board member** | **High-GDP (%)** | **Low-GDP (%)** | **P value** |
| **Gastroenterologists** | **54.5** | **34.9** | **0.0001** |
| **Colorectal surgeons** | **51.6** | **26.0** | **0.0001** |
| **IBD nurses** | **51.6** | **26.0** | **0.0001** |
| **Radiologists** | **43.2** | **24.1** | **0.0001** |
| **Histopathologists** | **16.7** | **18.5** | **0.45** |
| **Nutritional specialist** | **14.0** | **8.7** | **0.006** |
| **Psychologists** | **4.3** | **3.6** | **0.6249** |
| **Pharmacist** | **6.3** | **2.5** | **0.002** |